Marinus Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Marinus Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Marinus Pharmaceuticals Inc Strategy Report
- Understand Marinus Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company. It discovers, develops and commercializes therapies for the treatment of rare genetic epilepsies and other seizure disorders. The company's product includes Ganaxolone, a novel gamma-aminobutyric acid (GABA) receptor modulator, which is developed in intravenous (IV) and oral formulations. Marinus Pharmaceuticals carries out research and development, educational grants, and other services. It markets products under the brand name Ztalmy. The company's product help in the treatment of acute and chronic care settings, seizure disorders, rare epilepsies, pediatric epilepsies, brain disorders, and other disorders. It serves healthcare providers, caregivers, healthcare professionals, and others. Marinus Pharmaceuticals is headquartered in Radnor, Pennsylvania, the US.
Headquarters
United States of America
Address
Three Radnor Corporate Center, 100 Matsonford Rd, Suite 304, Pennsylvania, 19087
Website
marinuspharma.com
Telephone
1 484 8014670
No of Employees
165
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MRNS (NASD)
Revenue (2022)
$31.0M
21.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-613.6%
(2022 vs 2021)
Market Cap*
$79.7M
Net Profit Margin (2022)
XYZ
-486.7%
(2022 vs 2021)
* As of and is in US$
Marinus Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ganaxolone | Ztalmy |
Competitor Comparison
| Key Parameters | Marinus Pharmaceuticals Inc | IPI Legacy Liquidation Co | bluebird bio Inc | Jazz Pharmaceuticals Inc | Leap Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Radnor | Seattle | Somerville | Palo Alto | Cambridge |
| State/Province | Pennsylvania | Washington | Massachusetts | California | Massachusetts |
| No. of Employees | 165 | 160 | 323 | - | 54 |
| Entity Type | Public | Private | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Scott Braunstein, M.D. | President; Chief Executive Officer; Chairman | Executive Board | 2022 | 59 |
| Steven E. Pfanstiel | Chief Financial Officer; Chief Operating Officer; Treasurer | Senior Management | 2021 | 50 |
| Joseph Hulihan | Chief Medical Officer | Senior Management | 2019 | 67 |
| Alex Aimetti, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Sasha Damouni Ellis | Senior Vice President - Corporate Affairs and Investor Relations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer